A head-to-head study between two popular weight loss drugs, Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, showed that users lost more weight using Zepbound.
According to the study, which was sponsored by Lilly, people using Zepbound lost 20.2% of their body weight over 72 weeks, while Wegovy users lost 13.7%. In pounds, that means Zepbound users lost an average of 50 lbs, while Wegovy users lost 33.
This is the first time two of the drugs had a direct comparison. Previous studies explored the effectiveness of the drugs, which have been marketed to help obese users lose weight, but this blind trial specifically evaluated the two brands as both compete for market share in the lucrative weight loss drug market.
Dr. Susan Spratt, an endocrinologist and senior medical director for the Population Health Management Office at Duke Health in North Carolina, told NBC News that both drugs are effective. “The amount of weight loss with both is astounding,” she told the outlet.
The main difference between the two is that Zepbound contains the active ingredient tirzepatide, which is the same ingredient used in Lilly’s diabetes drug Mounjaro. Wegovy, meanwhile, uses semaglutide, the ingredient used in Novo Nordisk’s Ozempic, which is also prescribed to diabetes patients.
CHECK OUT THE DAILY WIRE HOLIDAY GIFT GUIDE
The GLP-1 drugs mimic a hormone that helps reduce food intake and appetite, causing users to eat less than they did before. Tirzepatide also imitates a second hormone, GIP, which is believed to help the body break down sugar and fat, NBC noted.
A spokesperson for Novo Nordisk said its drug Wegovy, in combination with diet and exercise, “is the only obesity medicine proven to reduce the risk of major cardiovascular events such as death, heart attack, or stroke.”
The drugs have become a hot topic of conversation as the demand outpaces the supply and a growing number of people seek their weight loss benefits. However, some unpleasant side effects of taking these types of drugs include gastrointestinal problems, including abdominal pain, nausea, and vomiting. There is also a potential risk of thyroid tumors and cancer associated with Ozempic, another popular option, according to studies done with rodents, as The Daily Wire previously reported.
